Parenteral Drug Manufacturing—CDMO Outlook: A Capacity Crunch or Easing?

What is the supply and demand outlook for fill–finish capacity in the CDMO/CMO sector? Is a capacity crunch or capacity ease in the making? And how will hot-product areas, such as GLP-1 agonist impact market fundamentals?

Ian Tzeng, Managing Director and Partner, L.E.K. Consulting

Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals and vaccines, and leads L.E.K.’s Pharmaceutical Contract Services Practice. 

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights. Or get each episode through:

For a full list of the 2025 podcast episode schedule, click here.

You May Also Like

Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead

By
What will be the key issues shaping bio/pharma supply chains in 2025? Looking at the impact of potential changes in US tariff and trade policy. Plus, what lies ahead in…